This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.
The respiratory system hosts a large and diverse number of microorganisms, which function as a unit and are associated with human health and disease states. Distinct compositions of microbiota are associated with the development of distinct immune dysfunctions, including inflammatory bowel disease, pediatric asthma, acute pneumonia and chronic rhinosinusitus, and are also associated with significant differences in clinical outcomes. Currently, microbiota are not considered during diagnosis of lung or nasal dysbiosis. This invention identifies microbial endotypes that would benefit from differentiated therapy.
This novel invention provides the following benefits:
-Rapid access to testing results
-Relatively inexpensive testing
-Opportunity to implement precision medicine
Researchers at the University of California, San Francisco have demonstrated that distinct populations of microbiota in patients with acute infection or chronic inflammatory disease are associated with distinct immune dysfunction and differences in clinical response. They have developed a method to obtain a microorganism sample and probe the microorganism population to identify diversity and plurality of microbiota.
-Identify distinct populations of microbiota in patients
-Develop tailored treatment based on microbiota composition
To develop and commercialize this technology to stratify and treat nasal and lung dysbiosis patients
Susan Lynch, PhD http://profiles.ucsf.edu/susan.lynch
|Patent Cooperation Treaty||Published Application||WO2018209307||11/15/2018||2017-187|
|Patent Cooperation Treaty||Published Application||WO2018209308||11/15/2018||2017-187|
Microorganisms, Nasal dysbiosis, Lung dysbiosis, Respiratory system, Immune dysfunction, Inflammatory disease